Stock BRTX BIORESTORATIVE THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News BioRestorative Therapies, Inc.

Equities

BRTX

US0906556065

Real-time Estimate Cboe BZX
Other stock markets
 02:20:31 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.275 USD +3.66% Intraday chart for BioRestorative Therapies, Inc. -5.84% -25.86%
Apr. 16 BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment DJ
Apr. 16 BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment
DJ
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial
MT
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
AQ
BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
CI
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
AQ
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
CI
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
AQ
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
AQ
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
AQ
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting
CI
Top Midday Decliners
MT
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
AQ
Top Premarket Decliners
MT
BioRestorative Therapies Reports Positive Results From Lumbar Disc Treatment Candidate Trial; Shares Rise
MT
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
AQ
BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
CI
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
AQ
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
AQ
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BRTX Stock
  4. News BioRestorative Therapies, Inc.